179 related articles for article (PubMed ID: 25078338)
1. Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study.
Lorusso D; Martinelli F; Mancini M; Sarno I; Ditto A; Raspagliesi F
Int J Gynecol Cancer; 2014 Sep; 24(7):1256-61. PubMed ID: 25078338
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
Dandamudi RK; Aslam S; Walji N; El-Modir A; Fernando I
Anticancer Res; 2015 Sep; 35(9):4841-7. PubMed ID: 26254376
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant chemotherapy in uterine carcinosarcoma: Comparison of a doublet and a triplet chemotherapeutic regimen.
Maheshwari U; Rajappa SK; Talwar V; Goel V; Dash PK; Sharma M; Goyal P; Jain P; B Koyyala VP; Doval DC
Indian J Cancer; 2021; 58(2):179-184. PubMed ID: 33753600
[TBL] [Abstract][Full Text] [Related]
4. Carcinosarcoma of the ovary.
Silasi DA; Illuzzi JL; Kelly MG; Rutherford TJ; Mor G; Azodi M; Schwartz PE
Int J Gynecol Cancer; 2008; 18(1):22-9. PubMed ID: 17451459
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma.
Lacour RA; Euscher E; Atkinson EN; Sun CC; Ramirez PT; Coleman RL; Brown J; Gano JB; Burke TW; Ramondetta LM
Int J Gynecol Cancer; 2011 Apr; 21(3):517-22. PubMed ID: 21436700
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma.
Einstein MH; Klobocista M; Hou JY; Lee S; Mutyala S; Mehta K; Reimers LL; Kuo DY; Huang GS; Goldberg GL
Gynecol Oncol; 2012 Jan; 124(1):26-30. PubMed ID: 22055846
[TBL] [Abstract][Full Text] [Related]
7. Carcinosarcoma of the ovary-a case series.
Rutledge TL; Gold MA; McMeekin DS; Huh WK; Powell MA; Lewin SN; Mutch DG; Johnson GA; Walker JL; Mannel RS
Gynecol Oncol; 2006 Jan; 100(1):128-32. PubMed ID: 16213011
[TBL] [Abstract][Full Text] [Related]
8. A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
Makker V; Abu-Rustum NR; Alektiar KM; Aghajanian CA; Zhou Q; Iasonos A; Hensley ML
Gynecol Oncol; 2008 Nov; 111(2):249-54. PubMed ID: 18755503
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
Powell MA; Filiaci VL; Rose PG; Mannel RS; Hanjani P; Degeest K; Miller BE; Susumu N; Ueland FR
J Clin Oncol; 2010 Jun; 28(16):2727-31. PubMed ID: 20421537
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel and carboplatin in patients with completely or optimally resected carcinosarcoma of the uterus: a phase II trial by the Japanese Uterine Sarcoma Group and the Tohoku Gynecologic Cancer Unit.
Otsuki A; Watanabe Y; Nomura H; Futagami M; Yokoyama Y; Shibata K; Kamoi S; Arakawa A; Nishiyama H; Katsuta T; Kudaka W; Shimada M; Sato N; Kotera K; Katabuchi H; Yaegashi N
Int J Gynecol Cancer; 2015 Jan; 25(1):92-7. PubMed ID: 25347097
[TBL] [Abstract][Full Text] [Related]
11. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Wolfson AH; Brady MF; Rocereto T; Mannel RS; Lee YC; Futoran RJ; Cohn DE; Ioffe OB
Gynecol Oncol; 2007 Nov; 107(2):177-85. PubMed ID: 17822748
[TBL] [Abstract][Full Text] [Related]
12. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Homesley HD; Filiaci V; Markman M; Bitterman P; Eaton L; Kilgore LC; Monk BJ; Ueland FR;
J Clin Oncol; 2007 Feb; 25(5):526-31. PubMed ID: 17290061
[TBL] [Abstract][Full Text] [Related]
13. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery.
Matsuo K; Johnson MS; Im DD; Ross MS; Bush SH; Yunokawa M; Blake EA; Takano T; Klobocista MM; Hasegawa K; Ueda Y; Shida M; Baba T; Satoh S; Yokoyama T; Machida H; Ikeda Y; Adachi S; Miyake TM; Iwasaki K; Yanai S; Takeuchi S; Nishimura M; Nagano T; Takekuma M; Shahzad MMK; Pejovic T; Omatsu K; Kelley JL; Ueland FR; Roman LD
J Surg Oncol; 2018 Mar; 117(3):488-496. PubMed ID: 29044542
[TBL] [Abstract][Full Text] [Related]
14. Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Aghajanian C; Sill MW; Secord AA; Powell MA; Steinhoff M
Gynecol Oncol; 2012 Sep; 126(3):424-7. PubMed ID: 22634397
[TBL] [Abstract][Full Text] [Related]
15. A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
Dickson EL; Vogel RI; Gehrig PA; Pierce S; Havrilesky L; Secord AA; Dottino J; Fader AN; Ricci S; Geller MA
Gynecol Oncol; 2015 Nov; 139(2):275-82. PubMed ID: 26348313
[TBL] [Abstract][Full Text] [Related]
16. Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
Brackmann M; Stasenko M; Uppal S; Erba J; Reynolds RK; McLean K
BMC Cancer; 2018 Feb; 18(1):172. PubMed ID: 29426293
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
Sutton G; Kauderer J; Carson LF; Lentz SS; Whitney CW; Gallion H;
Gynecol Oncol; 2005 Mar; 96(3):630-4. PubMed ID: 15721404
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study.
Takano T; Otsuki T; Tokunaga H; Toyoshima M; Utsunomiya H; Nagase S; Niikura H; Ito K; Yaegashi N; Yamada H; Tase T; Kagabu M; Shoji T; Sugiyama T; Sato N; Fujimoto T; Terada Y; Nakahara K; Kurachi H; Yokoyama Y; Mizunuma H; Soeda S; Nishiyama H; Matsumoto T; Sato S; Shimada M; Kigawa J
Int J Clin Oncol; 2014 Dec; 19(6):1052-8. PubMed ID: 24395448
[TBL] [Abstract][Full Text] [Related]
19. Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Ebata T; Yonemori K; Nishikawa T; Sudo K; Shimomura A; Noguchi E; Fujiwara Y; Kato T; Hasegawa K; Fujiwara K; Tamura K
Oncology; 2020; 98(10):699-705. PubMed ID: 32526764
[TBL] [Abstract][Full Text] [Related]
20. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
Sutton G; Brunetto VL; Kilgore L; Soper JT; McGehee R; Olt G; Lentz SS; Sorosky J; Hsiu JG
Gynecol Oncol; 2000 Nov; 79(2):147-53. PubMed ID: 11063636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
